Compare Arqit Quantum Inc (ARQQ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Novartis AG — how do they compare? Arqit Quantum Inc trades at $24.48 (market cap $424.79M), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 695.3× Arqit Quantum Inc's market cap, and Novartis AG pays a 3.07% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ARQQ | NVS | |
|---|---|---|
Market Cap | $424.79M | $295.37B |
Sector | Technology | Health |
52-Week High | $58.27 | $168.62 |
52-Week Low | $11.78 | $119.31 |
Enterprise Value | $398.10M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $22.90, up 6.66% with bullish technical signals from moving averages and ADX indicators. The company shows explosive revenue growth (829% YoY in H1 FY26) but remains deeply unprofitable with a -4,508% net margin and negative cash flow from operations. Recent news highlights quantum-safe encryption partnerships and government contract wins, though financial sustainability concerns persist.
The stock presents high-risk speculation on quantum security adoption versus fundamental weaknesses. Upside depends on commercializing technology into sustainable profits, while downside risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold with no institutional conviction evident in current financial metrics.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
